Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 35,371 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Breast Cancer Female
Interventions: Starting the Conversation Video, Sexual and Menopausal Health Resources; Behavioral
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 21 Years and older · Female only
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cervical Cancer
Interventions: GSK1120212 (trametinib), GSK2141795; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Paroxetine Hydrochloride Controlled-Release Tablets 25 mg, Paxil CR™ Tablets 25 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy Male Adults, Food Effect in Healthy Volunteers
Interventions: AJ201; Drug
Lead sponsor: AnnJi Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Los Alamitos, California

Conditions: Acne
Interventions: EQ Exfoliating Cleanser, EQ Gel, EQ Moisturizer; Other
Lead sponsor: Menning Labs; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Cervical Spine Fusion
Interventions: Anterior Cervical Discectomy & Fusion, Application of ADAM mechanoacoustic skin sensor; Procedure · Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 88 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Drug Interactions
Interventions: Rosuvastatin, Rosuvastatin + BAY1817080; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Healthy
Interventions: Daratumumab, Placebo, rHuPH20; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Social Anxiety Disorder, Public Speaking Fear, Public Speaking Anxiety, Social Fear
Interventions: Group Exposure for Social Anxiety, Self-Compassion Enhanced Group Exposure Therapy for Social Anxiety, Peer-Enhanced Group Exposure Therapy for Social Anxiety, Peer and Self-Compassion Enhanced Group Exposure Therapy for Social Anxiety; Behavioral
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 18 Years to 30 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Hepatocellular Carcinoma
Interventions: Percutaneous Local Ablation, Hypofractionated Image Guided Radiation Therapy; Procedure · Radiation
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Durham, North Carolina

Conditions: EWINGS SARCOMA
Interventions: Rabbit anti-thymocyte globulin, Busulfan, Melphalan, Fludarabine, Cyclophosphamide; Drug
Lead sponsor: University of Louisville; Other
Eligibility: Up to 30 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Knowledge, Attitudes, Practice
Interventions: No message, Culture-centric message, General messge; Other
Lead sponsor: South Dakota State University; Other
Eligibility: 18 Years and older
Enrollment: 408 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Rapid City, South Dakota

Conditions: Generalized Myasthenia Gravis
Interventions: efgartigimod PH20 SC; Biological
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 13
States / cities: Carlsbad, California • Palo Alto, California • Boca Raton, Florida + 10 more

Conditions: Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus, SJIA, AOSD, MAS
Interventions: Emapalumab; Drug
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: 6 Months to 80 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 9
States / cities: Birmingham, Alabama • Los Angeles, California • Gainesville, Florida + 6 more

Conditions: Age-Related Macular Degeneration
Interventions: DE-120, Aflibercept; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 14
States / cities: Phoenix, Arizona • Bakersfield, California • Walnut Creek, California + 11 more

Conditions: Refractory Malignancy
Interventions: Capecitabine and Sorafenib; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pulmonary Arterial Hypertension
Interventions: Macitentan; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 8
States / cities: Boston, Massachusetts • Minneapolis, Minnesota • St Louis, Missouri + 5 more

Conditions: Central Vein Cannulation
Interventions: Central Vein Cannulation; Device
Lead sponsor: Clear Guide Medical; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Restless Legs Syndrome
Interventions: Gabapentin Enacarbil (GEn), Placebo; Drug
Lead sponsor: Cleveland Sleep Research Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Middleburg Heights, Ohio

Conditions: Peripheral Artery Disease, Peripheral Vascular Diseases, Peripheral Arterial Disease, Peripheral Arterial Occlusive Disease
Interventions: Vumerity, Placebo; Drug · Other
Lead sponsor: University of Nebraska; Other
Eligibility: 50 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Diabetes Mellitus Type II, Hypertension
Interventions: Integrated CHW Intervention, CHW Session 1 Only; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Atlanta, Georgia • New York, New York

Conditions: Rheumatoid Arthritis
Interventions: Pedometer, Educational materials, Step count goals; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Scar, Skin Scarring, Skin Cancer, Wound Heal, Wound of Skin, Surgical Wound, Patient Satisfaction, Patient Preference, Surgical Incision
Interventions: Hydrocolloid dressing, Petrolatum jelly dressing; Device · Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Carmel, Indiana

Conditions: Logopenic Progressive Aphasia, Primary Progressive Aphasia
Interventions: High-definition active tDCS (HD-tDCS) + "Repeat After Me" (RAM) Treatment, Sham + "Repeat After Me" (RAM) Treatment; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 50 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Addressing Sexual Concerns in Breast Cancer: Patient Intervention Study

GSK1120212+GSK2141795 for Cervical Cancer

Food Study of Paroxetine Hydrochloride Controlled-Release Tablets 25 mg to Paxil CR™ Tablets 25 mg

A Study to Evaluate the Effect of Food on the Bioavailability of AJ201, and Safety, Tolerability, and Pharmacokinetics of AJ201 in Japanese and White Healthy Male Participants

A Single Group Study to Evaluate the Efficacy of a Cosmetic Product Line on Acne Symptoms

Measuring Dysphagia After ACDF Surgery Through A Novel Wearable Sensor

Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants

Group Exposure Workshops for Socially Anxious Undergraduates

Trial Comparing PLA to HIGRT (PROVE-HCC)

Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma

Palliative Care Messaging for American Indians

Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis

Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE

A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration

Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors

REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension

Image Guidance for Improved Vessel Cannulation in Pediatric Patients

Effects of Gabapentin Enacarbil on Arousals, Heart Rate, Blood Pressure and PLMs in Restless Legs Syndrome

Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease

Scaling Telehealth Models to Improve Co-morbid Diabetes and Hypertension (Phase II)

Trial of a Physical Activity Intervention for RA Fatigue

Scar Appearance After Postoperative Hydrocolloid Dressing Versus Standard Petrolatum Ointment

Targeting Language-specific and Executive-control Networks With Transcranial Direct Current Stimulation in Logopenic Variant PPA